NCT05232266

The Effectiveness of a Caralluma Fimbriata Extract on Stress, Sleep and Neurotransmitters

The Effectiveness of a Caralluma Fimbriata Extract on Stress, Sleep and Neurotransmitters, a Randomised Placebo-controlled Double-blind Study

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 129 (actual)
• Sponsor: RDC Clinical Pty Ltd · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This is a double blind, randomised, placebo-controlled clinical trial aiming to assess the effectiveness of Caralluma fimbriata on stress, sleep and neurotransmitters in a healthy adult population.

Conditions

• Stress
• Sleep

Interventions

Type	Name	Description
DRUG	Caralluma Fimbriata	Caralluma fimbriata in capsule form - taken as a 500mg dose (two 250mg capsules) twice daily, morning and evening with food.
DRUG	Placebo comparator - Microcrystalline cellulose	Placebo comparator in capsule form - taken as a 500mg dose (two 250mg capsules) twice daily, morning and evening with food.

Timeline

• Start date: 2022-02-10
• Primary completion: 2023-05-19
• Completion: 2023-05-19
• First posted: 2022-02-09
• Last updated: 2023-10-24

Locations

1 site across 1 country: Australia